Royal Berkshire NHS Foundation Trust

Posted March 29, 2021

29/03/2021 – Pioneering radiotherapy technology launched at Berkshire Cancer Centre, based at Royal Berkshire NHS Foundation Trust

Pioneering radiotherapy technology, which will revolutionise the way some cancer patients are treated, is being launched at the Berkshire Cancer Centre (BCC), based at Reading’s Royal Berkshire NHS Foundation Trust (RBFT) this week.

Studies have shown that SABR – Stereotactic Ablative Body Radiotherapy – can be more effective than traditional radiotherapy for some cancers because it delivers a far more powerful, targeted beam of high energy X-rays directly to a tumour.

This means the tumour receives a very large dose in fewer treatments and fewer visits to the department for patients.

SABR’s higher precision means the very intensive beams are targeted exactly on the tumour. Initially it will be used to treat lung cancer patients but the plan is to then roll it out to treat other appropriate cancers for which benefit has been proven.

Read the full press release by clicking here or on the image above.